Ann Doherty

If you made any changes in Pure these will be visible here soon.

Websites

http://www.cfgenetherapy.org.uk/

Fingerprint

Dive into the research topics where Ann Doherty is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

17 Article
2 Meeting abstract
1 Commissioned report

Association of genetic liability for psychiatric disorders with accelerometer-assessed physical activity in the UK Biobank.
Dennison, CA., Legge, SE., Bracher-Smith, M., Menzies, G., Escott-Price, V., Smith, DJ., Doherty, AR., Owen, MJ., O'Donovan, MC. & Walters, JTR., 26 Mar 2021, In: PLoS ONE.
Research output: Contribution to journal › Article › peer-review

Open Access
File
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
Alton, E. WFW., Beekman, J. M., Boyd, A. C., Brand, J., Carlon, M. S., Connolly, M. M., Chan, M., Conlon, S., Davidson, H., Davies, J. C., Davies, L. A., Dekkers, J. F., Doherty, A., Gea-sorli, S., Gill, D. R., Griesenbach, U., Hasegawa, M., Higgins, T. E., Hironaka, T., Hyndman, L., & 18 othersMcLachlan, G., Inoue, M., Hyde, S. C., Innes, J. A., Maher, T. M., Moran, C., Meng, C., Paul-Smith, M. C., Pringle, I. A., Pytel, K. M., Rodriguez-Martinez, A., Schmidt, A. C., Stevenson, B., Sumner-Jones, S. G., Toshner, R., Tsugumine, S., Wasowicz, M. W. & Zhu, J., Feb 2017, In: Thorax. 72, 2, p. 137-147
Research output: Contribution to journal › Article › peer-review

Open Access
File
A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis
Alton, E. W., Armstrong, D. K., Ashby, D., Bayfield, K. J., Bilton, D., Bloomfield, E. V., Boyd, A. C., Brand, J., Buchan, R., Calcedo, R., Carvelli, P., Chan, M., Cheng, S. H., Collie, D. S., Cunningham, S., Davidson, H. E., Davies, G., Davies, J. C., Davies, L. A., Dewar, M. H., & 60 othersDoherty, A., Donovan, J., Dwyer, N. S., Elgmati, H. I., Featherstone, R. F., Gavino, J., Gea-sorli, S., Geddes, D. M., Gibson, J. S., Gill, D. R., Greening, A. P., Griesenbach, U., Hansell, D. M., Harman, K., Higgins, T. E., Hodges, S. L., Hyde, S. C., Hyndman, L., Innes, J. A., Jacob, J., Jones, N., Keogh, B. F., Limberis, M. P., Lloyd-evans, P., Maclean, A. W., Manvell, M. C., Mccormick, D., Mcgovern, M., Mclachlan, G., Meng, C., Montero, M. A., Milligan, H., Moyce, L. J., Murray, G. D., Nicholson, A. G., Osadolor, T., Parra-leiton, J., Porteous, D. J., Pringle, I. A., Punch, E. K., Pytel, K. M., Quittner, A. L., Rivellini, G., Saunders, C. J., Scheule, R. K., Sheard, S., Simmonds, N. J., Smith, K., Smith, S. N., Soussi, N., Soussi, S., Spearing, E. J., Stevenson, B. J., Sumner-jones, S. G., Turkkila, M., Ureta, R. P., Waller, M. D., Wasowicz, M. Y., Wilson, J. M. & Wolstenholme-hogg, P., Jul 2016, NHS National Institute for Health Research. 240 p. (Efficacy and Mechanism Evaluation; vol. 3, no. 5)
Research output: Book/Report › Commissioned report

Open Access
File
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial
Alton, E. W. F. W., Armstrong, D. K., Ashby, D., Bayfield, K. J., Bilton, D., Bloomfield, E. V., Boyd, A. C., Brand, J., Buchan, R., Calcedo, R., Carvelli, P., Chan, M., Cheng, S. H., Collie, D. D. S., Cunningham, S., Davidson, H. E., Davies, G., Davies, J. C., Davies, L. A., Dewar, M. H., & 60 othersDoherty, A., Donovan, J., Dwyer, N. S., Elgmati, H. I., Featherstone, R. F., Gavino, J., Gea-sorli, S., Geddes, D. M., Gibson, J. S. R., Gill, D. R., Greening, A. P., Griesenbach, U., Hansell, D. M., Harman, K., Higgins, T. E., Hodges, S. L., Hyde, S. C., Hyndman, L., Innes, J. A., Jacob, J., Jones, N., Keogh, B. F., Limberis, M. P., Lloyd-evans, P., Maclean, A. W., Manvell, M. C., McCormick, D., McGovern, M., McLachlan, G., Meng, C., Montero, M. A., Milligan, H., Moyce, L. J., Murray, G. D., Nicholson, A. G., Osadolor, T., Parra-leiton, J., Porteous, D. J., Pringle, I. A., Punch, E. K., Pytel, K. M., Quittner, A. L., Rivellini, G., Saunders, C. J., Scheule, R. K., Sheard, S., Simmonds, N. J., Smith, K., Smith, S. N., Soussi, N., Soussi, S., Spearing, E. J., Stevenson, B. J., Sumner-jones, S. G., Turkkila, M., Ureta, R. P., Waller, M. D., Wasowicz, M. Y., Wilson, J. M. & Wolstenholme-hogg, P., Sep 2015, In: The Lancet Respiratory Medicine. 3, 9, p. 684-691
Research output: Contribution to journal › Article › peer-review

Open Access
File
Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation
Horsley, A. R., Davies, J. C., Gray, R. D., Macleod, K. A., Donovan, J., Aziz, Z. A., Bell, N. J., Rainer, M., Mt-Isa, S., Voase, N., Dewar, M. H., Saunders, C., Gibson, J. S., Parra-Leiton, J., Larsen, M. D., Jeswiet, S., Soussi, S., Bakar, Y., Meister, M. G., Tyler, P., & 12 othersDoherty, A., Hansell, D. M., Ashby, D., Hyde, S. C., Gill, D. R., Greening, A. P., Porteous, D. J., Innes, J. A., Boyd, A. C., Griesenbach, U., Cunningham, S. & Alton, E. W., Jun 2013, In: Thorax. 68, 6, p. 532-539 8 p.
Research output: Contribution to journal › Article › peer-review

Ann Doherty

Personal profile

Websites

Fingerprint

Research output

Association of genetic liability for psychiatric disorders with accelerometer-assessed physical activity in the UK Biobank.

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial

Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation